Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246158 | 0.89 | NPC1 (0.44) | NPC1LMNAPKMSMN1; SMN2MEN1 | |
| SCHEMBL3442720 | 0.85 | NPC1 (0.46) | NPC1LMNAPKMSMN1; SMN2MEN1 | |
| SCHEMBL3442722 | 0.85 | NPC1 (0.41) | NPC1LMNAPKMSMN1; SMN2MEN1 | |
| SCHEMBL13673252 | 0.85 | NPC1 (0.46) | NPC1LMNAPKMSMN1; SMN2MEN1 | |
| SCHEMBL10246492 | 0.84 | KMT2A (0.45) | NPC1LMNAPKMSMN1; SMN2MEN1 | |
| SCHEMBL10246135 | 0.82 | NPC1 (0.41) | NPC1LMNAPKMSMN1; SMN2MEN1 | |
| SCHEMBL4347398 | 0.79 | P2RX7 (0.34) | NPC1LMNAPKMSMN1; SMN2GAA | |
| SCHEMBL4347076 | 0.76 | LMNA (0.35) | NPC1LMNAPKMMEN1KMT2A | |
| SCHEMBL3406629 | 0.76 | LMNA (0.36) | NPC1LMNAPKMRORCPOLB | |
| SCHEMBL701075 | 0.76 | NPC1 (0.52) | NPC1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| EP-2262791-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009124746-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124746-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124734-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124734-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124733-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | NPC1 2399/4885LMNA 2546/4885PKM 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.